CTNNB1 and Parkinson disease: These effects have been linked to changes in the activity of beta-Catenin, a transcriptional cofactor that upregulates the expression of canonical Wnt target genes, that it has been found reduced in sporadic PD and cell carrying Leucine-rich repeat serine/threonine-protein kinase (LRPK)2 and beta-glucosidase PD-linked mutations (Marchetti, 2018).